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Abstract
Background: Several observations suggest that immunological events early after chemotherapy, possibly during the 
period of severe treatment-induced cytopenia, are important for antileukemic immune reactivity in acute myeloid 
leukemia (AML). We therefore investigated the frequencies of various T cell subsets (TC1, TH1, TH17) and CD25+ FoxP3+ 
TREG cells in AML patients with untreated disease and following intensive chemotherapy.
Results: Relative levels of circulating TC1 and TH1 cells were decreased in patients with severe chemotherapy-induced 
cytopenia, whereas TH17 levels did not differ from healthy controls. Increased levels of regulatory CD25+ FoxP3+ T cells 
were detected in AML patients with untreated disease, during chemotherapy-induced cytopenia and during 
regeneration after treatment. TH17 and TH1 levels were significantly higher in healthy males than females, but this 
gender difference was not detected during chemotherapy-induced cytopenia. Finally, exogenous IL17-A usually had 
no or only minor effects on proliferation of primary human AML cells.
Conclusions: We conclude that the effect of intensive AML chemotherapy differ between circulating T cell subsets, 
relative frequencies of TH17 cells are not affected by chemotherapy and this subset may affect AML cells indirectly 
through their immunoregulatory effects but probably not through direct effects of IL17-A.
Background
Acute myeloid leukemia (AML) is characterized by clonal
expansion of immature myeloblasts in the bone marrow
and eventually leukemization [1]. The only curative treat-
ment is intensive chemotherapy that can be combined
with stem cell transplantation especially in younger
patients below 60-65 years of age [1]. This treatment is
followed by a period of severe bone marrow failure with
severe pancytopenia, including lymphopenia. Rapid lym-
phoid reconstitution after therapy is associated with
increased AML-free survival, an observation strongly
suggesting that immunological events early after chemo-
therapy are clinically important [2,3]. This association
between reconstitution and survival has been observed
after conventional intensive chemotherapy [4], autotrans-
plantation [5] and allotransplantation [6,7]. The mecha-
nisms behind these associations are not known but may
involve (i) treatment-induced immunogenic cell death
with translocation of endo-calreticulin to the cell surface
and induction of antileukemic T cell reactivity [8], (ii)
increased efficiency of antileukemic immune reactivity
during this period of low leukemia cell burden, or (iii)
treatment-induced alterations of immunoregulatory net-
works. The remaining lymphocytes during chemother-
apy-induced cytopenia may thus be important for this
antileukemic effect.
Previous studies have described increased levels of cir-
culating immunosuppressive CD4+ CD25HIGH TREG cells
for patients with untreated AML [9,10] and these
increased levels persist after chemotherapy when com-
plete hematological remission is achieved [9]. The pre-
treatment TREG levels even seem to predict the response
to the chemotherapy [9]. The peripheral blood levels of
proinflammatory TH17 cells and IL17 plasma levels are
also suggested increased in untreated AML, but in con-
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remission is achieved [11]. However, the levels of various
T cell subsets during the early period of chemotherapy-
induced cytopenia have not been investigated previously,
and in the present study we therefore compared the T cell
subset distribution for AML patients (i) before treatment,
(ii) during the period of severe chemotherapy-induced
cytopenia, and (iii) during hematopoietic reconstitution
after treatment. The T cell subsets investigated were
IFNγ secreting CD8+ cytotoxic T (TC1) and CD4+ helper
T (TH1) cells, IL17-A secreting CD4+ helper (TH17) cells
and CD4+ CD25+ FoxP3+ regulatory T (TREG) cells.
Methods
Patients
The studies were approved by the local Ethics Committee
(Regional Ethics Committee III, University of Bergen,
Bergen, Norway). All blood samples were collected after
informed consent. AML was diagnosed according to the
WHO criteria [12].
Patients with newly diagnosed AML
In our studies of primary human AML cells we included
unselected patients with high peripheral blood blast
counts; enriched leukemic cell populations could then be
prepeared by density gradient separation alone (see
below).
AML patients receiving intensive chemotherapy
Samples for analysis of T cell subsets were obtained from
20 patients receiving intensive cytarabine-based therapy
(referred to as the first cohort). All patients were sampled
between 0730 and 0900 a.m., and the analysis of samples
or preparation of cultures started within 3 hours after
sampling. These patients represent a consecutive group
admitted to our hospital for either induction or consoli-
dation therapy. For all patients receiving induction che-
motherapy (i.e. patients with detectable AML prior to
treatment) examination of bone marrow samples drawn
during cytopenia 14 days after start of therapy verified
that leukemic cells could no longer be detected; these
patients were only included after the bone marrow con-
trol. The other patients were tested following consolida-
tion therapy, i.e. they had achieved disease control and
were in complete hematological remission before treat-
ment. Thus, none of the patients had detectable disease
when tested during cytopenia. Most of our patients (n =
16; median age 57.5 years with range 30-64 years; 5 males
and 11 females) were investigated during the period of
severe chemotherapy-induced cytopenia with peripheral
blood neutrophils < 0.5 × 109/L and dependency on regu-
lar platelet transfusion to maintain blood platelets > 10-
20 × 109/L. The last four patients were only investigated
during the regeneration after cytopenia. The patients
tested during pancytopenia were also lymphopenic with
total lymphocyte counts in peripheral blood < 0.5 × 109/
L.
Six patients in this first group (median age 55.5 years
with range 39-64 years; 2 males and 4 females) were
examined during hematopoietic reconstitution, i.e.
within 10 days after stable peripheral blood neutrophils >
0.5 × 109/L. Four of these patients had reached hemato-
logical remission prior to sampling (i.e. they received
consolidation chemotherapy); the last two patients
reached complete remission within one week after sam-
pling (i.e. they received induction chemotherapy).
We also analyzed the peripheral blood levels of various
T cell subsets in a second group of 8 patients that repre-
sent a consecutive group investigated during a one month
period (median age 50 years with range 17-67 years; 5
males and 3 females). This group is referred to as the sec-
ond cohort. The absolute as well as the relative levels of
various T cell subsets were investigated before (only
available for 6 patients), during and following chemother-
apy-induced cytopenia for the patients; paired statistical
analyses were thereby possible.
Two additional groups with cytopenic patients were
also examined. Firstly, we used a whole blood assay to
investigate the polyclonal T cell release of IL17-A after
activation with anti-CD3 + anti-CD28 + eventually IL2.
In this assay cell separation procedures are avoided by
diluting heparinized blood with culture medium, and T
cells are activated by specific anti-CD3/antiCD28 anti-
bodies during culture in this plasma/medium mixture as
described below (see the chapter "Cell culture"). The in
vitro assay and the patient characteristics have been
described in detail in a previous publication [13]. Sec-
ondly, we investigated the IL17-A release by a panel of T
cell clones derived from patients with therapy-induced
cytopenia; these patients and the preparation and charac-
terization of the clones have also been described previ-
ously [14-16].
Healthy controls
The controls (n = 30; median age 49.5 years with variation
range 21-64 years; 16 male and 14 female) did not differ
significantly with regard to age and sex from the patients
tested for T cell subset distribution during chemother-
apy-induced cytopenia. However, the controls were
younger than the patients with untreated disease. Before
statistical comparisons we therefore investigated whether
there was any age-dependent difference among the con-
trols, and if this was detected we compared untreated
patients with those controls being above 50 years of age
(n = 15).
Preparation of enriched AML cells
Leukemic peripheral blood mononuclear cells (PBMC)
were isolated by density gradient separation (Ficoll-
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1.077) from the peripheral blood of patients with a high
percentage of AML blasts among blood leukocytes (>
85%). Cells were cryopreserved in 20% heat-inactivated
fetal calf serum (FCS) plus 10% dimethylsulphoxide
(DMSO) and stored in liquid nitrogen. The studies of T
cell subsets included 16 unselected patients (median age
62.5 years with variation range 24-82 years; 7 males and 9
females). These cells are also referred to as primary
human AML cells (> 95% leukemia cells). Leukemic
PBMC were also used for analysis of T cell responsiveness
after stimulation with anti-CD2 + anti-CD3 as described
below for the whole blood assay.
Flow cytometry
Intracellular IL17-A, IFNγ and FoxP3 in T cells
Sodium Heparin blood samples were obtained and eryth-
rocytes lysed by BD Pharm Lyse solution (BD Biosci-
ences, Trondheim, Norway). Cryopreserved leukemic
PBMC were also analyzed. Pre-warmed X-Vivo 10® cul-
ture medium (BioWhittaker, Cambridge, MA, USA) was
added and the cell concentration adjusted to 106 cells/mL
before incubation for 4 hours with or without 2 μL/mL of
Leukocytes Activation cocktail with BD GolgiPlug (BD
Biosciences; PMA/Ionomycin/BFA) at 37°C in a humidi-
fied atmosphere of 5% CO2. The cells were thereafter
washed in ice-cold 1% BSA/PBS followed by staining with
PerCP-conjugated mouse anti-human CD3 (SK7; BD Bio-
sciences), FITC-conjugated anti-CD8 (RPA-T8; BD Bio-
sciences), FITC-conjugated anti-CD4 (RPA-T4; BD
Pharmingen) and/or PE-conjugated anti-CD25 (M-A251;
BD Biosciences) on ice for 20 minutes. Samples were
washed once in PBS before fixation and permeabilization
using eBioscience Fixation/Permeabilization Concentrate
(cat. 00-5123), Fixation/Permeabilization Diluent (cat.
00-5223) and Permeabilization Buffer (cat. 00-8333)
(eBioscience, San Diego, USA) as recommended by the
manufacturer. Intracellular staining was performed at
room temperature for 30 minutes with the mouse mono-
clonal Alexa Fluor 647-conjugated anti-human IL17-A
(eBio64DEC17; eBioscience), Alexa Fluor 647-conjugated
anti-FoxP3 (259D/C7, BD Biosciences), PE-conjugated
anti-IL17-A (eBio64CAP17; eBioscience) or PE-conju-
gated anti-IFNγ (B27; BD Biosciences). Four-color flow
cytometry was performed by a FACS Calibur System. For
each sample at least 20 000 lymphocytes were counted.
Results were analyzed by FlowJo software (Tree Star, Inc.,
OR, USA).
Estimation of absolute lymphocyte counts
Absolute count determination was done according to the
manufacturer's specifications. Briefly, samples were incu-
bated with anti-human CD3-PerCP (BD) for 20 minutes
before addition of Flow-Count Fluorospheres (Beckman
Coulter, London, UK), followed by immediate analysis by
a FACS Calibur System. For each sample 5000 beads were
counted. Results were analyzed by FlowJo software (Tree
Star).
Analysis of IL17 receptor (IL17-R) expression by primary 
human AML cells
Cells were stained with unconjugated mouse anti-human
IL17-R (clone 133617; R&D systems, Abingdon, UK)
using QIFIKIT (Dako, Glostrup, Denmark) in combina-
tion with anti-CD34 conjugated with APC (BD Biosci-
ences). The analysis was performed according to the
manufacturer's instructions. Gates for viable leukemia
cells were based on forward and side scatter and 20 000
events were collected.
Analysis of STAT, p38, CREB, Erk1/2 and Akt phosphorylation 
in primary AML cells
As described previously [17], AML cells were incubated
for 5 minutes with or without IL17-A, GM-CSF or IFN-γ
before STAT, p38, CREB, Erk1/2 and Akt phosphoryla-
tion were analyzed by using Alexa647-conjugated anti-
phospho-Stat5 (pY694), anti-phospho-Erk1/2 (pT202/
pY204) and anti-phospho-Akt (pS473); and Alexa488-
conjugated anti-phospho-Stat3 (pY705), anti-phospho-
p38 (pT180/pY182) and anti-phospho-Creb (pS133)
monoclonal antibodies (BD Biosciences).
Cell culture
Whole blood assay for analysis of IL17-A release
The standardization of this in vitro assay has been
described in detail in a previous methodological publica-
tion [18], and its use for analysis of T cell cytokine
responses in patients with chemotherapy-induced
cytopenia has also been described previously [13]. Briefly,
heparinized blood samples were diluted with growth
medium; cells were thereafter incubated in this plasma/
medium mixture and T cells activated with anti-CD3 and
anti-CD28 (The Central Laboratory of the Netherlands
Red Cross Blood Transfusion Services, Amsterdam, The
Netherlands). The T cell concentration in the cultures
was < 20 × 104/mL. Cultures were incubated for 4 days at
37°C in a humidified atmosphere of 5% CO2 before super-
natants were harvested and IL17-A levels determined
(Quantikine ELISA kits, R&D Systems). Even though sev-
eral leukocyte subsets are present in these cultures, it
should be emphasized that in our experiments we com-
pared differences in cytokine levels for cultures with and
without T cell activation signals (anti-CD3 and anti-
CD28), and the most likely explanation for increased
cytokine levels after T cell directed signaling is increased
release by activated T cells.
Proliferation studies of primary human AML cells
This in vitro assay has been described previously [19].
Briefly, 5 × 104 cells/well were incubated in flat-bottomed
microtiter plates (Costar 3796; Cambridge, MA, USA) in
150 μl Stem Span SFEM™ medium (Stem Cell Technolo-
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μg/mL of gentamicin and eventually 50 ng/ml of IL17,
IL1RA, IL1β, IL3, Flt3L, SCF, GM-CSF or G-CSF (Pepro-
Tech EC Ltd., London, UK). Proliferation was assayed as
3H-thymidine incorporation after 7 days.
Statistical analysis
The SPSS software was used to perform Wilcoxon's test
for paired samples, Mann-Whitney test for unpaired
samples, Spearman's rho for correlation or linear bivari-
ate regression analysis.
Results
Relative levels of CD3+ T cells are increased in AML patients 
with therapy-induced cytopenia
We investigated the levels of circulating CD3+ T cells for
patients with untreated AML (n = 16) and leukemia
patients with severe chemotherapy-induced cytopenia (n
= 16) and during reconstitution after chemotherapy (n =
6). Patients were compared with healthy controls (n = 30)
and the overall results are presented in Figure 1A. As
expected the percentage of CD3+ T cells among total leu-
kocytes was decreased and depended on the degree of
leukemization for patients with untreated disease. During
chemotherapy-induced cytopenia significantly increased
levels of circulating CD3+ T cells were observed (gener-
ally > 60%; median level 91.5%), and very few normal
(monocytes, granulocytes) and leukemic myeloid cells
remained. During hematopoietic reconstitution (i.e. cir-
culating neutrophils > 0.5 × 109 /L) the percentage of
CD3+ T cells showed an expected normalization although
a wide variation was observed among the patients.
We then compared the relative CD3+ T cell levels
among total lymphocytes in the patient groups (Figure
1A). For some untreated patients the lymphocytes and
AML cells had overlapping side and forward scatter (for a
detailed discussion see [20]), and these patients (5/16)
had to be excluded from this analysis. Patients with che-
motherapy-induced cytopenia showed significantly
increased percentages of CD3+ cells among total lympho-
cytes compared to healthy controls and patients with
untreated disease. The CD3+ percentage thereafter nor-
malized during hematopoietic reconstitution, although
the variation range was wider than for the controls.
The relative levels of CD8+ and CD4+ T cells are normal 
following intensive chemotherapy
The levels of circulating CD8+ cytotoxic (TC) and CD8-
(referred to as CD3+ CD4+) helper (TH) T cells among
total CD3+ T cells were determined in all three patient
groups (Figure 1B). The TC and TH levels showed only
minor variations in the AML patients and did not differ
significantly from the healthy controls. However, both for
TC and TH cells the variation ranges were generally wider
for patients with untreated disease and severe chemo-
therapy-induced cytopenia than for the patients in the
reconstitution phase and for healthy controls.
Circulating TC1 and TH1 cells are decreased during severe 
chemotherapy-induced cytopenia
Patients were investigated for relative levels of circulating
TC1 and TH1 cells among CD3+ T cells by intracellular
IFNγ staining. Gating strategies are shown in Figure 2A
(upper part) and the overall results for patients and
healthy controls are presented in Figure 3. Relative levels
of TC1 cells, defined by the expression of CD3+ CD8+ and
IFNγ+, were normal in untreated AML. However, the lev-
els were decreased during chemotherapy-induced
Figure 1 Relative levels of total T cells and T cell subsets 
(CD3+CD8+ and CD3+CD4+) in AML patients receiving intensive 
chemotherapy. T cell levels were investigated for patients with un-
treated AML (AML, n = 16), patients with chemotherapy-induced cy-
topenia (Cytopenia, n = 16; the first cohort of patients) and during 
hematopoietic reconstitution after chemotherapy (Reconstitution, n = 
6); these results were compared with healthy controls (n = 30). A. The 
levels of circulating CD3+ T cells are presented as the percentages of 
total viable leukocytes (left panel) or total lymphocytes (right panel). B. 
The levels CD8+ (TC) and CD4+ (i.e. CD3+CD8- cells referred to as CD4+ 
TH cells) T cell levels are presented as the percentages of positive cells 
among total CD3+ lymphocytes. All results are presented as median 
(horizontal line), 25th to 75th percentiles (boxes) and variation range 
(whiskers). The percentages of total T cells or T cell subsets did not 
show any age-dependent variation among the healthy controls. Statis-
tically significant differences are indicated at the top of the figures 
(Mann-Whitney test).
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compared to the controls (median level 41.6%, range 8-
65%) before normalization during reconstitution (median
level 56%, range 23-86%). Relative levels of TH1 cells,
defined by the phenotype CD3+ CD8- IFNγ+, were also
significantly decreased during therapy-induced cytopenia
(median level 9.5%, range 1-45%) compared to the con-
trols (median level 17%, range 4-45%) before normaliza-
tion occurred during reconstitution (median level 16.5%,
range 9-21%). Finally, the absolute levels of TC1 and TH1
cells were also decreased and significantly correlated
when investigated in the second cohort of patients (p <
0.005).
Relative levels of circulating TH17 cells are maintained in 
AML patients with chemotherapy-induced cytopenia
The patients were examined for relative levels of circulat-
ing TH17 cells by intracellular staining against IL17-A fol-
lowed by flow cytometric analysis. Gating strategies are
Figure 2 Strategies for flow-cytometric analysis of intracellular 
IL17-A, IFNγ and FoxP3. Peripheral blood lymphocytes were incubat-
ed for 4 hours with PMA/Ionomycin/BFA (IL17 and IFNγ) or in medium 
alone (FoxP3) followed by intracellular staining and analysis by flow cy-
tometry. A. IFNγ and IL17-A accumulation in CD8- (referred to as CD4+ 
cells) after 4 hours of stimulation with PMA/Ionomycin/BFA. The detec-
tion of IL17-A in CD8- (CD4+) T cells was verified by using two different 
antibodies. B. The levels of regulatory T cells were analyzed by detec-
tion of CD4+ CD25+ FoxP3+ cells. For both panels CD3+ CD8+ T cells 
were used as negative intra-sample controls for both TH17 and TREG 
cells.
Figure 3 The TC1, TH1 and TH17 subsets in AML patients and 
healthy controls. The levels of circulating TC1, TH1 and TH17 cells were 
investigated for patients with untreated AML (AML, n = 16), patients 
with chemotherapy-induced cytopenia (Cytopenia, n = 16; the first co-
hort of patients) and during hematopoietic reconstitution after che-
motherapy (Reconstitution, n = 6); these results were compared with 
healthy controls (n = 30). The levels for each of the subsets are present-
ed as the percentage of each cell type among the parent population; 
i.e. TC1 cells among CD8+ cells, TH1 and TH17 cells among CD8- T cells 
and TREG cells among CD4+ T cells. All results are presented as median 
(horizontal line), 25th to 75th percentiles (boxes) and variation range 
(whiskers). The percentages of total T cells or T cell subsets did not 
show any age-dependent variation among the healthy controls. Statis-
tically significant differences are presented at the top of the figure 
(Mann-Whitney test).
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for patients and healthy controls are presented in Figure
3. The relative levels of circulating TH17 cells, defined by
the phenotype CD3+ CD8- IL17-A+, did not differ
between healthy controls and AML patients with
untreated disease, treatment-induced cytopenia and
regeneration after chemotherapy. However, patients with
untreated disease and chemotherapy-induced cytopenia
showed wider variation ranges than the other groups.
We examined levels of IL17-A in culture supernatants
when T cells among leukemic PBMC (n = 17, T cell con-
centration in cultures < 2 × 104/mL) were activated with
anti-CD3 plus anti-CD28 as described for the whole
blood assay. Detectable IL17-A levels up to 90 pg/mL
were observed after T cell activation; this is similar to
normal PBMC (T cell concentration 2-3 × 105/mL) that
also showed detectable release up to 87 pg/mL (data not
shown). Thus, because this IL17-A release occurred in
response to T cell specific stimulation (anti-CD3 + anti-
CD28) the most likely explanation for the increased levels
is that the ability of circulating T cells to release IL17-A is
maintained in the presence of primary AML cells even
though these cells show constitutive release of several
immunoregulatory cytokines [21]. IL17 levels are actually
higher for untreated patients than for the controls when
considering the different T cell concentrations in the cul-
tures.
We investigated the polyclonal T cell release of IL17-A
for another group of AML patients with chemotherapy-
induced cytopenia [13]; peripheral blood leukocytes were
then cultured in a whole blood assay and IL17-A levels
determined in the culture supernatants (see Additional
file 1: Figure S1). Samples cultured in medium alone or
with isotypic control antibodies usually showed unde-
tectable (23 out of 25 samples) or low IL17-A levels (< 37
pg/mL). Detectable levels were present only for a minor-
ity of samples (6/25) after stimulation with anti-CD3 +
anti-CD28 and anti-CD3 + anti-CD28 + IL2, but these
levels were significantly higher than for the correspond-
ing unstimulated control cultures (p = 0.027). An unse-
lected subset of 17 consecutive samples was in addition
cultured with the antileukemic drug Pep005 [13,22] in
combination with anti-CD3 + anti-CD28 + IL2. Pep005
significantly increased the IL17-A levels compared with
the corresponding drug-free controls, and detectable lev-
els were then observed for 11 of the 17 samples (see Addi-
tional file 1: Figure S1). Finally we compared IL17-A
levels with the levels of IFNγ, GM-CSF, IL2, IL3, IL4, IL5,
IL6, IL10, IL13 and TNFα after T cell activation with anti-
CD3 + anti-CD28 and anti-CD3 + anti-CD28 + IL2. GM-
CSF was the only cytokine that showed statistically signif-
icant correlations with IL17-A both after stimulation with
anti-CD3 + anti-CD28 (p < 0.001, rho = 0.5) and anti-
CD3 + anti-CD28 + IL2 (p = 0.001, rho = 0.5). Thus, the
remaining TH17 cells in cytopenic patients are functional
and because these increased levels occurred after T cell-
specific stimulation with anti-CD3 + anti-CD28 the most
likely explanation is that the remaining T cells are able to
release detectable IL17-A in response to adequate stimu-
lation as a part of a broad cytokine response.
We compared phytohemagglutinin and anti-CD3 stim-
ulated IL17-A release by a panel of T cell clones derived
from another group of cytopenic patients [14-16].
Detectable IL17 release was observed for 5 out of 51
CD4+ CD8- T cell clones and 2 out of 36 CD4- CD8+
clones. These results further confirmed that IL17-A-
releasing T cells (i.e. TH17 cells) remain in the circulation
during severe chemotherapy-induced cytopenia. How-
ever, the IL17-A levels were relatively low (15- 26 pg/ml)
for those clones with detectable release. All the IL17-A
releasing T cell clones were CD2+ CD3+ CD19- TCRαβ+
TCRγδ- CD57- and additionally released IFNγ and GM-
CSF (data not shown).
Thus, only a minority of remaining clonogenic T cells is
able to release detectable IL17-A and the frequencies are
comparable to those detected by the flow cytometry
assay.
Relative levels of circulating CD4+ CD25+ FoxP3+ T cell are 
increased in AML patients before and following intensive 
chemotherapy
The relative levels of circulating TREG cells were deter-
mined for all the patients by intracellular staining against
FoxP3 and analysis by flow cytometry. Gating strategies
are shown in Figure 2B and the overall results are pre-
sented in Figure 4. Increased levels of natural TREG cells,
defined by the phenotype CD3+ CD4+ CD25+ FoxP3+,
were detected for AML patients with untreated disease,
chemotherapy-induced cytopenia and regeneration after
treatment when compared with healthy controls. The
TREG levels were highest for patients with untreated dis-
ease and chemotherapy-induced cytopenia; thereafter the
levels decreased significantly but were still higher than
for the controls. As an alternative strategy for analysis of
TREG cells we determined the percentage of
CD3+CD4+CD25HIGH cells in all the samples (Figure 4).
The analysis confirmed that the highest levels of TREG
cells were detected in patients with untreated leukemia
and during chemotherapy-induced cytopenia (Figure 4).
The FoxP3+ and CD25HIGH TREG levels were significantly
correlated both in patients with untreated leukemia and
during chemotherapy-induced cytopenia (p < 0.001).
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significant correlations in AML patients with untreated 
disease and treatment-induced cytopenia
We compared the levels of circulating TC1, TH1, TH17
and Treg cells for patients and healthy controls (Figure
5A). Significant correlations between the levels of circu-
lating TH17 and TH1 cells were detected for AML patients
with untreated disease and during chemotherapy-
induced cytopenia; this correlation was stronger for
untreated (r2 = 0.67) than for cytopenic patients (r2 =
0.34) and no correlation was found during reconstitution
and for in healthy controls. Even though we also found
significant correlations between TH1 and Tc1 levels for all
groups except patients in reconstitution (Figure 5A), the
TH17 and TC1 levels showed no correlation (data not
shown). Finally, TREG cells showed no significant correla-
tions with any other T cell subset (data not shown). These
observations were also confirmed when investigating
absolute T cell counts in the second cohort of patients;
TH17 and TH1 levels then showed a highly significant cor-
relation (p < 0.001), whereas TREG cells showed no signifi-
cant correlations with any other T cell subset.
TH17 and TH1 levels are significantly higher in healthy 
males than females but this gender-dependent difference 
is not detected after intensive AML chemotherapy
Significantly higher levels of circulating TH17 cells were
observed for healthy males (Figure 5B; n = 16, median
levels 2.3% range 1.1-5.0%) compared with females (n =
14; median 1.9%, range 0.8-3.3%; p = 0.02). This differ-
ence was detected both for younger and elderly controls.
A similar difference was also observed when comparing
male (n = 7; median 4.2%, range 0.6-7.2) and female (n =
9; median 1.0, range 0.3-3.3) patients with untreated
AML, although it reached only borderline significance (p
= 0.06). In contrast, TH1 levels differed between males
and females when comparing the elderly controls above
50 years of age but not when comparing the whole con-
trol group; a similar difference of borderline significance
(Figure 5B; p = 0.05) was observed only for patients with
untreated disease. No gender differences in TH17 and
Figure 4 Circulating FoxP3+ TREG cells and CD4+ CD25HIGH T cells in 
AML patients and healthy controls. The levels of CD4+ FoxP3+ TREG 
cells and CD3+ CD4+ CD25HIGH T cells were analyzed for patients with 
untreated AML (AML, n = 16), patients with chemotherapy-induced cy-
topenia (Cytopenia, n = 16; the first cohort of patients) and during he-
matopoietic reconstitution after chemotherapy (Reconstitution, n = 6); 
these results were compared with healthy controls (n = 30). The levels 
are presented as the percentage of each cell type among CD4+ T cells. 
No age-dependent differences were observed in the control group. All 
results are presented as median (horizontal line), 25th to 75th percen-
tiles (boxes) and variation range (whiskers). Statistically significant dif-
ferences are presented at the top of the figures (Mann-Whitney test).
Figure 5 Peripheral blood levels of TH1 and TH17 cells; analysis of 
covariation between various T cell subsets and differences be-
tween males and females. A. Bivariate regression analysis was used 
to analyze the correlations between TH1/TC1 and TH1/TH17 cell subsets 
in AML patients with untreated disease (AML, n = 16) and patients with 
chemotherapy-induced cytopenia (Cytopenia, n = 16; the first cohort 
of patients); these results were compared with healthy controls (n = 
30). The levels are presented as the percentage of each cell type 
among the parent population, i.e. TC1 cells among CD8+ T cells, TH1 
and TH17 cells among CD8- T cells. The p- and r2-values for each analy-
sis are indicated in each figure. B. Analysis of TH1 and TH17 levels in 
male and female healthy controls (all controls and those controls older 
than 50 years) and patients with untreated AML patients. The levels are 
presented as the percentage of each cell type among CD8- T cells. All 
results are presented as the median (line within the box), 25th to 75th 
percentiles (box) and variation ranges (whiskers), are presented as per-
centages of parent. P-values are given in each figure.
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Page 8 of 12TH1 levels were seen for AML patients during cytopenia
or reconstitution (data not shown). Finally, the levels of
circulating T cell subsets showed no significant correla-
tions with cytogenetics, induction or consolidation che-
motherapy or serum level of C reactive protein at the
time of sampling.
Acute leukemia patients with severe chemotherapy-
induced pancytopenia: studies of absolute levels of various 
T cell subsets in a second cohort of patients
We investigated relative and absolute T cell levels in a
second cohort of 8 consecutive AML patients receiving
intensive chemotherapy. For all patients the relative TREG
levels were increased during cytopenia (median level
10%, range 7-32%) compared with pretherapy levels
(median level 3%, range 2-16%) and the levels detected
during early reconstitution (median 7%, range 5-13%).
The absolute TREG cell counts showed a wide variation
between the patients during cytopenia (median counts
14.1 cells/μl, range 5.6-59.8), and this wide variation per-
sisted during the early hematopoietic reconstitution with
increasing neutrophil counts (median counts 24.6 cells/
μl, range 6.8-60.8). For two of these patients the absolute
TREG counts increased markedly during cytopenia com-
pared with the pretherapy and early regeneration levels;
levels up to 59.8 cells/μL were then observed and this
increase was not accompanied with an increase of total
CD4+ T cells. In contrast to TREG levels, the absolute TH17
cell counts showed only minor variations in individual
patients during cytopenia; the counts were within the
range of 3-10.9 cells/μL, and for 3 of the 8 patients stable
counts below 5 cells/μl were detected. Pretherapy levels
were generally within the same range (1.1-17.5 cells/μl),
whereas the absolute TH17 levels showed a wider varia-
tion during early reconstitution (median counts 13.4
cells/μl, range 1.0-35.0). Thus, these results support the
data from the first patient cohort: absolute and relative
levels of circulating TREG cells are increased during
cytopenia whereas the TH17 levels only shows minor
variations after chemotherapy.
We also compared the TC1:TREG, TH1:TREG and
TH17:TREG ratios for patients tested before, during and
following severe chemotherapy-induced cytopenia (Fig-
ure 6). All ratios decreased during cytopenia, i.e. the lev-
els of the three other subsets decreased compared with
the TREG levels. Finally, when comparing the overall
results TREG and TH17 absolute cell counts showed no
statistically significant correlation; this is similar to the
observations in the first cohort.
IL17-A has only minor effects on the functional 
characteristics of primary human AML cells
TH17 cells and IL17 have important immunoregulatory
functions but also an additional regulatory role in normal
Figure 6 Peripheral blood T cell levels in AML patients receiving 
intensive chemotherapy; TC1:TREG, TH1:TREG and TH17:TREG ratios 
determined before, during and following severe treatment-in-
duced cytopenia. The TC1:TREG, TH1:TREG and TH17:TREG ratios were de-
termined before (B), during (D) and after (A) severe chemotherapy-
induced cytopenia for patients included in the second cohort. All re-
sults are presented as absolute cell concentration in peripheral blood 
(cells per μL blood) for TC1, TH1 or TH17 cells relative to the correspond-
ing levels of TREG cells. Each line indicates the results for one patient, 
and P-values are given in each figure (Wilcoxon for paired samples).
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Page 9 of 12hematopoiesis [23]. Furthermore, previous studies have
also demonstrated that IL17-RB can be expressed by
t(8;21)-positive AML cells [24]. For these reasons we
investigated whether IL17 had a direct role in regulation
of leukemic hematopoiesis; this has been described for
several other T cell derived cytokines [25-27]. First we
investigated IL17-R expression by primary AML cells
derived from 13 consecutive patients. For 10 of these
patients we detected a small IL17-R+ CD34- leukemic
subpopulation (see Additional file 2: Figure S2; median
level of IL17-R+ leukemic cells being 9%, variation range
1.5 - 34.7%); and none of these patients expressed the
genetic t(8;21) abnormality. Furthermore, when compar-
ing the overall results for the 13 patients we did not
observe any significant alteration in the phosphorylation
status of intracellular Stat3, Stat5, p38, Erk1/2, Creb and
Akt after IL17-R ligation, although responses were
observed for some individual patients (see Additional file
2: Figure S2). An expected intracellular phosphoresponse
was observed after exposure to GM-CSF and IFNγ (data
not shown).
We also investigated whether IL17-A had any effects on
AML cell proliferation. The overall results are shown in
Additional file 3: Table S1. Leukemic cells derived from
59 consecutive patients were cultured in vitro with and
without IL17-A 50 ng/mL. Detectable spontaneous pro-
liferation corresponding to at least 1000 counts per min-
ute (cpm) was observed only for 13/59 patients, and IL17-
A caused a significant enhancement of the in vitro prolif-
eration (median 6386 cpm; interquartile range 11.826
cpm: p = 0.002). The leukemic cells were also cultured
with and without IL17-A in the presence of 50 ng/mL of
IL1RA, IL1β, IL3, Flt3L, SCF, G-CSF or GM-CSF. IL17-A
caused a minor, though statistically significant, increase
of cytokine-dependent proliferation in the presence of
IL1β, IL3, SCF, G-CSF and GM-CSF. However, the
increase exceeded 2000 cpm and corresponded to > 20%
of the IL17-A-free control only for a small minority of
patients. IL17-A had no significant effect on clonogenic
AML cell proliferation and did not affect the constitutive
AML cell release of IL1β, IL6 and TNFα (data not
shown). To summarize, IL17A-R is expressed only by a
minority of primary AML cells, receptor ligation usually
does not induce detectable intracellular phosphore-
sponses and exogenous IL17-A has only minor effects on
functional AML cell characteristics.
Discussion
Previous studies of TREG cells in human AML have
included patients with untreated disease and patients in
complete hematological remission. AML patients with
chemotherapy-induced cytopenia have not been exam-
ined, even though clinical studies suggest that immuno-
logical events early after chemotherapy are important for
the antileukemic effect of chemotherapy. In the present
study we therefore compared T cell subset distribution in
AML patients with severe chemotherapy-induced
cytopenia with (i) untreated patients or patients during
regeneration after intensive chemotherapy; and (ii)
healthy controls. The cytopenic patients had increased
relative levels of circulating TREG cells, whereas levels of
TC1 and TH1 cells were decreased while TH17 cells were
not altered.
Early lymphoid reconstitution after chemotherapy is
associated with decreased risk of leukemia relapse [4-
7,28], and these observations suggest that immunological
events early after chemotherapy are clinically important.
The immunological status during treatment-induced
cytopenia are determined by pre-existing disease-
induced abnormalities and chemotherapy-induced
defects [21]. Previous studies have demonstrated that
even patients with severe therapy-induced lymphopenia
have an operative T cell system [21], and in this context
we investigated the balance between various proinflam-
matory and suppressive T cell subsets in AML patients.
As expected the relative levels of CD3+ T lymphocytes
to total leukocytes were dependent on the degree of leu-
kemization in patients with untreated AML. More
important, the frequencies of circulating CD3+ T cells
among total lymphocytes were decreased in patients with
untreated disease compared with healthy controls, these
levels were increased during chemotherapy-induced pan-
cytopenia before normalization during reconstitution.
Even though our cytopenic patients had lymphopenia,
our results suggest that CD3+ T cells are less sensitive to
intensive chemotherapy than myeloid cells and other
lymphocyte subsets (e.g. B cells, NK cells).
We did not find any significant differences in relative
CD8+ and CD4+ T cell levels between healthy controls
and patients examined before or following intensive che-
motherapy. In contrast, the relative levels of circulating
IFNγ secreting CD4+ (TH1) and CD8+ (TC1) T cells were
decreased in cytopenic patients before normalization
during reconstitution (Figure 3). This decrease is also
reflected in the decreased TC1:TREG and TH1:TREG ratios
during cytopenia (Figure 6). Taken together these obser-
vations strongly suggest that treatment-induced lym-
phopenia is not a random process and the susceptibility
to intensive chemotherapy differ between T cell subsets.
TH17 cells constitute a separate proinflammatory T
helper (TH) cell subset [29-33]. Studies in animals as well
as humans suggest that TH17 cells are important for anti-
cancer immune reactivity [34,35]. A previous study
described increased frequencies of circulating TH17 cells
in patients with untreated AML and with a normalization
when patients achieved complete remission after chemo-
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Page 10 of 12therapy [11]. In contrast, we observed normal TH17 levels
for patients with untreated AML. In addition we
observed that functional TH17 cells could be detected
during severe therapy-induced cytopenia, and these fre-
quencies did not differ from healthy controls although
the variation range was broader. Studies of absolute and
relative TH17 levels in a second patient cohort confirmed
that only minor variations were seen during therapy-
induced cytopenia. The decreased TH17:TREG ratio dur-
ing cytopenia is thus caused by relatively stable TH17
absolute levels with only minor decreases and maintained
or increasing absolute levels of TREG cells (Figure 6).
Finally, we observed increased IL17-A release by circulat-
ing cells in response to stimulation by T cell specific anti-
bodies (anti-CD3 combined with anti-CD28); this is
probably caused by T cell release because IL17-A release
from other cells in response to these T cell specific stimu-
latory signals seems less likely. Our overall results thereby
strongly suggest that neither the leukemia nor the che-
motherapy has any selective suppressive effect on TH17
cells compared with other T cell subsets. Release of IL17-
A from other cells than T cells activated in response to
these stimulatory signals seems less likely.
Immunosuppressive CD4+ TREG cells inhibit effector T
cells and NK cells [36,37]. Depletion of TREG cells
enhances murine anti-cancer immunity [38,39] as well as
vaccine-induced anticancer reactivity in humans [40].
Increased levels of circulating TREG cells seem to occur in
untreated AML [9,10], although these previous studies
did not analyze FoxP3+ cells. We observed increased lev-
els of circulating FoxP3+ TREG cells in patients with
untreated AML. Even though previous studies suggest
that at least certain cytotoxic drugs can reduce the levels
of circulating TREG cells [41], our present results showed
that the frequencies of TREG cells were increased before
and following intensive AML chemotherapy. Studies in a
second cohort of patients demonstrated that the absolute
levels of Treg cells even increased during cytopenia for
certain patients. This was true even for patients regener-
ating after therapy, an observation that is also supported
by another study [9]. The relative levels of CD4+
CD25HIGH TREG cell were also increased in untreated
AML and during cytopenia. The variations of various T
cell subsets relative to TREG cells then suggest that the
various subsets are differentially affected, and the
increased TREG levels may then be caused either by TREG
proliferation or development from T cell progenitors or
other T cell subsets.
We observed a correlation between the levels of TH1
and TC1 cells both for AML patients and healthy con-
trols, and this correlation was maintained during severe
therapy-induced cytopenia. In contrast, the correlation
between TH1 and TH17 levels was detected only for AML
patients with untreated disease and therapy-induced
cytopenia. These observations further support the
hypothesis that various T cell subsets are differentially
affected in AML patients.
The levels of circulating TH17 cells were significantly
higher in males than females for healthy controls, and
TH1 cells were also higher in males for elderly controls. In
a recent gene expression study of activated T cells the
responsiveness was generally higher in women than in
men, but IL17-A was the only effector gene that showed
highest expression in men [42]. Estrogen response ele-
ments in the promoter regions of several immune genes
could possibly explain the gender differences [42]. This
gender differences reached only borderline statistical sig-
nificance for patients with untreated AML and could not
be detected in our cytopenic patients. Thus, the influence
of gender differences on circulating T cell subsets
becomes less important after chemotherapy.
Exogenous IL17-A had no or only weak effects on func-
tional AML cell characteristics; even though some differ-
ences were statistically significant their biological
significance can be questioned. Even though the relative
levels of TH17 cells are maintained after chemotherapy,
we conclude that TH17 cells may affect AML cells indi-
rectly through their immunoregulatory effects; whereas
direct effects of IL17-A on the leukemic cells probably do
not have any major impact.
Conclusions
To conclude, AML patients have an altered distribution
of circulating T cell subsets; this is due to both disease-
associated and chemotherapy-induced alterations
whereas gender-dependent differences in TH1 and TH17
levels become less important after intensive chemother-
apy. Our results suggest that TREG cells are relatively resis-
tant to intensive AML therapy as increased levels persist
even during the period of severe cytopenia. Previous
studies suggest a prognostic impact of TREG cells in AML
patients receiving intensive chemotherapy, but our pres-
ent results suggest that the altered TREG levels are only a
part of a more complex immunological phenotype in
these patients. Taken together our studies strongly sug-
gest that the possible prognostic impact of variations in
circulating T cell subsets should be addressed in future
clinical studies.
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